Actiq

Actiq, by Cephalon, is a recently-developed Category 2 solid formulation of fentanyl citrate on a stick that dissolves slowly in the mouth for transmucosal absorption.

Actiq is intended for opiate-tolerant individuals and is effective in treating breakthrough cancer pain. It is also useful for breakthrough pain for those suffering bone injuries, migraines, severe back pain, neuropathy, arthritis, and some other examples of chronic, non-malignant pain. The unit is a berry-flavored lozenge on a stick which is swabbed on the mucosal surfaces inside the mouth - under and on the tongue and gums - to release the fentanyl quickly into the system. It is most effective when the lozenge is consumed in exactly 15 minutes, as the balance of the drug absorbed through the cheeks and the amount swallowed is maintained. The drug is far less potent if consumed orally compared to sublingually. Actiq is available in 7 dosages, from 200 μg to 3,200 μg (there are no 1,000 μg or 1,400 μg doses, and it skips from 1,600 to 3,200 μg) in 200 μg increments. The 3,200 μg version is only available to cancer patients.

A sugar-free version is in development, and should be available beginning June 2006. Since the current version is held between the cheek and gum and contains sugar, it could lead to eventual tooth decay. Diabetics also need to take its sugar content into account. Side effects include the normal side effects found with this class of narcotic analgesic plus constipation and dry mouth. One 1,600 μg Actiq is 150 calories, making weight gain a problem for patients who consume many per day.

There have also been reports of illicit use.

© Medic8 ® All Rights Reserved.